CDK

Cat. No.

A54434

CAS No.

882291-64-7

KM05382

KM05382 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9), disrupting its activity and consequently leading to reduced transcription of the GAPDH gene. This compound plays a crucial role in regulating transcriptional control and has potential applications in understanding cell cycle dynamics and cancer research. Its unique mechanism makes it valuable for studies aimed at evaluating CDK9's role in gene expression and related pathways.

Cat. No.

A54436

CAS No.

959369-94-9

p27

p27 is a cyclin-dependent kinase (CDK) inhibitor that functions as a substrate for the SCFSkp2/Cks1 complex. This protein plays a crucial role in cell cycle regulation by inhibiting CDK activity, thereby impacting cell proliferation. p27 is widely used in cancer research to investigate the mechanisms of tumorigenesis and to explore therapeutic strategies for targeting cell cycle dysregulation.

Cat. No.

A54437

CAS No.

3033694-01-5

CLZX-205

CLZX-205 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9), exhibiting an IC50 of 2.9 nM. This compound is significant in cancer research due to its ability to inhibit the phosphorylation of RNA polymerase II, thereby impacting transcriptional regulation in oncogenic pathways. CLZX-205 serves as a valuable tool for studying CDK9-related mechanisms and therapeutic strategies in cancer biology.

Cat. No.

A54438

CAS No.

2761572-96-5

CDK9-IN-23

CDK9-IN-23 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9) with an IC50 value of less than 20 nM. This compound demonstrates effective inhibition of transcriptional regulation and is crucial for studying cellular processes such as proliferation and survival. CDK9-IN-23 is primarily used in research applications focused on cancer biology and the modulation of gene expression pathways.

Cat. No.

A54442

CAS No.

2035069-96-4

CDK4/6-IN-17

CDK4/6-IN-17 is a potent orally active inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), exhibiting an IC50 range of 10-100 nM in BE(2) cells. This compound effectively inhibits tumor growth in the COLO205 xenograft model, making it a valuable tool for cancer research focused on cell cycle regulation and therapeutic strategies targeting CDK4/6 pathways. Its application in preclinical studies provides insights into the mechanistic effects of CDK4/6 inhibition on tumor progression.

Cat. No.

A54443

CAS No.

3033950-86-3

CDK4/6-IN-19

CDK4/6-IN-19 is a selective inhibitor of CDK4 and CDK6, demonstrating IC50 values of 0.2 nM and 5.0 nM, respectively. It effectively inhibits cellular proliferation, making it a valuable reagent for cancer research applications, particularly in studies focused on cell cycle regulation and tumor growth. Its potent activity positions CDK4/6-IN-19 as a critical tool in evaluating potential therapeutic interventions against CDK4/6-dependent malignancies.

Cat. No.

A54444

CAS No.

1219915-83-9

CDK2-IN-15

CDK2-IN-15 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), exhibiting an IC50 of 2.9 μM. This compound plays a significant role in cancer research by modulating cell cycle progression and apoptosis. CDK2-IN-15 is suitable for studies aimed at understanding CDK2's role in tumorigenesis and potential therapeutic strategies in oncology.

Cat. No.

A54445

CAS No.

2640208-01-9

CDK7-IN-7

CDK7-IN-7 is a potent and selective inhibitor of cyclin-dependent kinase 7 (CDK7), demonstrating an IC50 of less than 50 nM. This compound effectively interferes with CDK7 activity, leading to reductions in transcriptional regulation and cellular proliferation. CDK7-IN-7 is valuable for research applications focused on cancer biology, transcription regulation, and therapeutic strategies targeting cell cycle dysregulation.

Cat. No.

A54447

CAS No.

2988020-03-5

CDK8-IN-15

CDK8-IN-15 is a selective inhibitor of cyclin-dependent kinase 8 (CDK8), exhibiting a potent IC50 of 57 nM. This compound enhances the thermal stability of CDK8 while effectively inhibiting NF-κB signaling pathways. CDK8-IN-15 demonstrates promising biological activity in an in vitro psoriasis model induced by TNF-α, alleviating inflammation and promoting the expression of anti-inflammatory markers such as Foxp3 and IL-10. This makes it a valuable tool for research into psoriasis and related inflammatory disorders.

Cat. No.

A54448

CAS No.

3031861-18-1

YJZ5118

YJZ5118 is a selective inhibitor of cyclin-dependent kinases 12 and 13 (CDK12/CDK13), demonstrating IC50 values of 39.5 nM and 26.4 nM, respectively. This compound suppresses the transcription of DNA damage response genes, induces DNA damage in tumor cells, and effectively inhibits cellular proliferation while triggering apoptosis. YJZ5118 specifically impedes RNA polymerase II Ser2 phosphorylation and enhances Akt pathway activity, exhibiting synergistic effects when combined with Akt inhibitors. It is a valuable research tool for studying various cancers, including prostate cancer.

Cat. No.

A54449

CAS No.

3027994-03-9

CDK4-IN-4

CDK4-IN-4 is a selective inhibitor of Cyclin-dependent kinase 4 (CDK4), with an IC50 value of less than 10 nM. This compound plays a critical role in cancer research by selectively interfering with cell cycle regulation, thus inhibiting the proliferation of cancer cells. CDK4-IN-4 is suitable for studies focusing on cell cycle dynamics and the therapeutic potential of CDK4 inhibition in various cancer models.

Cat. No.

A54450

CAS No.

1817006-50-0

CDK7-IN-5

CDK7-IN-5 is a selective inhibitor of cyclin-dependent kinase 7 (CDK7) with an IC50 value of less than 100 nM. This compound exhibits significant anticancer activity, making it a valuable tool in cancer research. Its ability to modulate transcriptional regulation positions CDK7-IN-5 as a promising candidate for studies aimed at investigating novel therapeutic strategies for cancer treatment.

Cat. No.

A54452

CAS No.

237392-85-7

Cdk2/Cyclin Inhibitory Peptide II

Cdk2/Cyclin Inhibitory Peptide II is a specific inhibitor of cyclin-dependent kinase 2 (CDK2), primarily influencing cell cycle regulation. This peptide has demonstrated the ability to induce apoptosis in U2OS osteosarcoma cells in a dose-dependent manner. Its application in research includes investigations into cell cycle dynamics and therapeutic strategies for cancer treatment.

Cat. No.

A54453

CAS No.

933009-51-9

CDK1-IN-7

CDK1-IN-7 is a potent inhibitor of Cyclin-dependent kinase 1 (CDK1). It effectively inhibits the proliferation and migration of colorectal cancer cell lines, including HCT116 and Lovo. This compound serves as a valuable tool for investigating the role of CDK1 in colorectal cancer research and therapeutic strategies.

Cat. No.

A54454

CAS No.

3038638-82-0

CDK2-IN-52

CDK2-IN-52 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), exhibiting an impressive DC50 value of 1-10 nM. This compound effectively induces cell cycle arrest and inhibits the proliferation of tumor cells, making it a valuable tool for studying CDK2-overexpressing malignancies such as breast and ovarian cancers. CDK2-IN-52 facilitates research into potential therapeutic strategies targeting CDK2 in cancer treatment.

Cat. No.

A54455

CAS No.

2862836-22-2

CDK2-IN-14

CDK2-IN-14 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), known for its potency in inhibiting cell cycle progression. This compound plays a significant role in cancer research, allowing for the exploration of CDK2's involvement in tumorigenesis and potential therapeutic interventions. CDK2-IN-14 is suitable for studies aimed at understanding the mechanisms of cell proliferation and offers potential insights into novel cancer treatment strategies.

Cat. No.

A54457

CAS No.

2380320-68-1

CDK4-IN-2

CDK4-IN-2 is a potent inhibitor of cyclin-dependent kinase 4 (CDK4) with a Ki and IC50 value of less than 10 nM. This compound effectively regulates cell cycle progression and is valuable in cancer research, particularly in studies focused on oncogenic signaling pathways and cell proliferation. It serves as a crucial tool for evaluating potential therapeutic strategies targeting CDK4 in various malignancies.

Cat. No.

A54458

CAS No.

3024545-83-0

CDK7-IN-29

CDK7-IN-29 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7) with an IC50 value of 1.4 nM. This compound demonstrates oral bioavailability and favorable pharmacokinetic properties, making it suitable for in vivo studies. Its ability to inhibit CDK7 positions it as a valuable tool for investigating cellular processes related to transcription and cell cycle regulation, particularly in cancer research applications.

Cat. No.

A54459

CAS No.

2850253-95-9

CDK8-IN-9

CDK8-IN-9 is a potent type II cyclin-dependent kinase 8 (CDK8) inhibitor, exhibiting an IC50 value of 48.6 nM. This compound effectively inhibits tumor growth and serves as a valuable tool in colorectal cancer research. Its targeting of CDK8 makes it suitable for investigations into the molecular mechanisms underlying cancer progression and treatment responses.

Cat. No.

A54460

CAS No.

3051587-93-7

CDK2-IN-44

CDK2-IN-44 is a potent inhibitor of cyclin-dependent kinase 2 (CDK2), a crucial regulator of the cell cycle. This compound effectively blocks the proliferation of cancer cells by inducing cell cycle arrest, promoting apoptosis, and triggering cellular senescence. CDK2-IN-44 is particularly relevant for research applications focused on ovarian and breast cancer, offering valuable insights into therapeutic strategies targeting CDK2 activity.

Cat. No.

A54461

CAS No.

2649407-21-4

Cdc7-IN-9

Cdc7-IN-9 is a selective inhibitor of the Cdc7 kinase, a key regulator of DNA replication and cell cycle progression. This compound demonstrates significant biological activity in inhibiting cancer cell proliferation by disrupting the replication process. Cdc7-IN-9 is valuable for research applications focused on understanding the role of Cdc7 in cancer biology and developing targeted therapies for tumor treatment.

Cat. No.

A54463

CAS No.

3039540-24-1

CDK9 ligand 3

CDK9 ligand 3 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9), known for its role in regulating transcriptional elongation. It serves as a crucial component in the synthesis of PROTAC CDK9 degrader-11, facilitating targeted protein degradation. This compound is valuable for research applications focused on cancer therapeutics and the modulation of gene expression through CDK9 inhibition.

Cat. No.

A54464

CAS No.

1908454-70-5

CDK4/6-IN-13

CDK4/6-IN-13 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), pivotal regulators of the cell cycle. This compound demonstrates low nanomolar potency, exhibiting significant antiproliferative activity against various cancer cell lines. CDK4/6-IN-13 also offers favorable metabolic properties and pharmacokinetic profiles, making it a valuable tool for research in oncology and cell cycle regulation.

Cat. No.

A54465

CAS No.

2146171-49-3

Fovinaciclibum

Synonyms: Fovinaciclib

Fovinaciclibum is a cyclin-dependent kinase (CDK) inhibitor that demonstrates significant antineoplastic activity. This compound is designed to selectively inhibit CDK enzymes, thereby disrupting cell cycle progression and promoting apoptosis in cancer cells. It is utilized in research focusing on tumor biology and therapeutic strategies for various malignancies.

Cat. No.

A54467

CAS No.

3032997-16-0

CDK1-IN-4

CDK1-IN-4 is a selective inhibitor of cyclin-dependent kinase 1 (CDK1), exhibiting IC50 values of 44.52 nM for CDK1, 624.93 nM for CDK2, and 135.22 nM for CDK5. This compound effectively disrupts the cell cycle, leading to inhibition of cancer cell proliferation. CDK1-IN-4 is suitable for research applications related to cancer biology and therapeutics targeting cell cycle regulation.